Abstract
Purpose: :
To establish a correlation between Central SD-OCT Thickness and Best Corrected Visual Acuity (BCVA) in a Type 2 Diabetes Non-Proliferative Retinopathy (NPDR) population, sampling by Diabetic Retinopathy (DR) progression stage.
Methods: :
Four-hundred and thirty-two (432) eyes from two-hundred and thirty-four (234) patients with Type 2 diabetes and NPDR were enrolled in an observational, prospective, cohort study to assess Genotype/Phenotype correlations in Type 2 DR. All patients underwent Color Fundus Photography (CFP), SD-OCT (Cirrus OCT, Carl Zeiss) and BCVA assessment. Following CFP analysis by an automated method for Microaneurism (MA) earmarking (RetmarkerDR, Critical Health, SA) patients were assigned to three groups according to their progression stage (DR0, no DR lesions; DR1, <5 MA count; DR2, ≥5 MA count and/or presence of exsudates). Correlation analysis was performed between Diabetes Duration, BCVA and SD-OCT Thickness for the central 1000µm in the different groups as well as for MA counting. Mean values for the different variables were: SD-OCT Thickness (DR0, 271.8 ±32 μm; DR1, 271.2 ±33 μm; DR2, 276.5 ±36 μm); BCVA (DR0, -0.24 ±0.03 logMAR; DR1, -0.23 ±0.04 logMAR; DR2, -0.24 ±0.04 logMAR); Diabetes Duration (DR0, 8.6 ±5 years; DR1, 9.4 ±4 years; DR2, 11.3 ±5 years).
Results: :
No correlation was found between SD-OCT Central Thickness and BCVA in neither of the 3 groups (DR0, r=-0.034; p=0.771 ; DR1, r=0.075; p=0.321; DR2, r=0.103; p=0.171) nor between MA counting and SD-OCT Central Thickness (DR0, r=0.121; p=0.302 ; DR1, r=-0.123; p=0.102; DR2, r=-0.007; p=0.927) and BCVA (DR0, r=-0.313; p=0.006 ; DR1, r=-0.106; p=0.159; DR2, r=-0.259; p>0.001). However a moderate correlation was found between BCVA and Diabetes Duration for the DR0 sample (DR0, r=0.431; p>0.001; DR1, r=0.224; p=0.003; DR2, r=0.21; p=0.776).
Conclusions: :
Central Thickness wasn’t found to be predictive of BCVA even when taking into account DR progression stage. Although MA counting has been showed as an appropriate marker of DR progression, it could not be established to predict BCVA or Central Thickness in a Type 2 NPDR population.
Clinical Trial: :
http://www.clinicaltrials.gov NCT01228981
Keywords: diabetic retinopathy • imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound)